TrialJournal of hematology & oncology2022

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.

Qian Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.